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The impact of azithromycin
therapy on the airway
microbiota in asthma
INTRODUCTION
There is interest in the use of macrolide
antibiotics in asthma. Macrolides have
been shown to improve airway hyper-
responsiveness (AHR) and measures of
airway inﬂammation.1 The degree of
AHR may relate to the microbiota present
in the airways,2 with a recent study
reporting that patients with asthma with a
signiﬁcant improvement in AHR follow-
ing treatment with clarithromycin had a
higher bacterial diversity prior to treat-
ment.3 To our knowledge, the impact on
the asthmatic airway microbiota of an
antibiotic has not been reported and we
therefore set out to establish if macrolide
therapy was associated with a change in
airway microbiota in asthma.
METHODS
Five adult patients with moderate/severe
asthma (British Thoracic Society step 4–5)
(see online supplementary table S1) and
no evidence of respiratory infection or
bronchiectasis underwent bronchoscopy
before and after 6 weeks of daily 250 mg
azithromycin therapy. Patients had con-
sented to the study (REC 11/EM/0062).
Saline washings of the right upper lobe
were obtained following standard proced-
ure, DNA was isolated from the samples
(see online supplementary Methods) and
the microbiota analysed by using pyrose-
quencing performed by Molecular
Research DNA. Microbiota results were
analysed after random resampling of the
data4 and calculation of two diversity
indices; richness and Shannon’s.
RESULTS
A total of 5223 reads were analysed from
ﬁve sample pairs (pretreatment and post-
treatment). Eighty-nine distinct genera
were detected. Bacteria from the genera
Staphylococcus (10.49%), Pseudomonas
(9.35%), Streptococcus (7.99%) and
Neisseria (4.75%) were all found to be
among the more abundant genera in the
pretreatment samples (table 1).
The total abundance of each genus is
given as a percentage of the total number
of reads within each of the three groups.
Parentheses represent the number of
samples where the genus was present.
Many genera reduced in abundance
after treatment including Prevotella
(3.43%), Staphylococcus (4.59%) and
Haemophilus (3.28%), with Pseudomonas
not detected post-treatment. There was an
increase in the relative number of
Anaerococcus (39.18%) observed in two
patients after treatment.
Evaluation of richness revealed that the
mean number of genera detected in the pre-
treatment samples was 19.37 genera
(SD=5.68, n=5). This was higher than the
mean number of genera post-treatment
(mean=12.80 genera, SD=3.70, n=5).
Equally, the mean Shannon’s index in the pre-
treatment group was 1.62 (SD=0.20, n=5)
compared with post-treatment (mean=1.22,
SD=0.40, n=5). Non-parametric investiga-
tion found near signiﬁcant differences
between the patients pretreatment and post-
treatment with richness and Shannon’s index
(both Kruskal-Wallis χ2=3.15, p=0.076;
ﬁgure 1).
CONCLUSION
This is the ﬁrst study to examine longitu-
dinal changes in airway microbiota follow-
ing antibiotic treatment in asthma.
Azithromycin therapy was associated with
decreased bacterial richness in the airways
and altered the airway microbiota leading
to Anaerococcus becoming dominant
within the bacterial community in some
cases. Importantly, Pseudomonas,
Haemophilus and Staphylococcus (three
pathogenic genera associated with airway
disease) were all reduced. This may
explain the clinical improvement observed
in asthma5 and suggests a possible anti-
biotic as well as immunomodulatory
effect of macrolides on AHR.
Azithromycin has also been shown to
decrease mucus secretion, airway neutro-
phil accumulation as well as speciﬁc
Table 1 Relative abundance of each of the most dominant genera in samples pretreatment
and post-treatment
Genus Total (n=10) Pretreatment (n=5) Post-treatment (n=5)
Actinobacillus 2.97 (1) 4.78 (1) 0.00 (0)
Anaerococcus 17.29 (5) 3.89 (3) 39.18 (2)
Fusobacterium 1.82 (4) 2.90 (3) 0.05 (1)
Haemophilus 7.91 (5) 10.74 (3) 3.28 (2)
Neisseria 3.01 (2) 4.75 (1) 0.15 (1)
Prevotella 4.12 (6) 4.54 (4) 3.43 (2)
Pseudomonas 5.80 (2) 9.35 (2) 0.00 (0)
Staphylococcus 8.25 (8) 10.49 (5) 4.59 (3)
Streptococcus 8.08 (6) 7.99 (3) 8.22 (3)
Veillonella 7.39 (6) 4.10 (3) 12.76 (3)
Other 7.37 (3) 7.99 (2) 6.35 (1)
Figure 1 Characteristics of the microbiota in patients prior to and after azithromycin treatment.
Each data point represents a single sample with horizontal lines indicating the mean number of
genera detected (A) and Shannon’s index rank (B). Near signiﬁcant differences were reported
between groups for both measures (χ2=3.15, p=0.076). Dotted lines are shown to indicate the
change in measure for each patient.
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antibiotic and antipseudomonal activity.
This early work indicates that larger
studies of the effect of treatments on the
airway microbiota and clinical outcomes
are now needed.
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